CD33 and acute myeloid leukemia: Treatments started 20 days after injection after the detection of human AML cells in mice blood and were given during 25 days, and disease propagation was evaluated by human CD33-positive (hCD33+) leukemic cells flow cytometry detection in mice blood until total tumor burden measure after sacrifice at day 57 (Fig. 6E).